Skip to content

The Intracept Global Registry ( TIGR ) - Pilot Study

The Intracept Global Registry

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04449835
Enrollment
30
Registered
2020-06-29
Start date
2020-07-31
Completion date
2022-12-01
Last updated
2023-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Low Back Pain

Brief summary

The Intracept Global Registry is a prospective, noninterventional, observational global post market independent data collection of the ongoing effectiveness, safety, and satisfaction outcomes for patients treated with the Intracept Procedure. This registry will be conducted according to Good Clinical Practice (GCP) guidelines, including participant verbal informed consent and Independent Review Board (IRB) / Ethics Committee (EC) approval and oversight. Registry design, conduct, analysis, and reporting are overseen by the Principal Investigator (PI) and the cross-specialty TIGR Physician Steering Committee.

Detailed description

Participants in the registry will have seven study visits over a period of five years (one prior to procedure and 6 post their procedure). Study visits will be conducted via telephone by a third-party CRO and independent clinical research coordinators. Participants will be verbally consented and then evaluated via telephonic study visits at baseline (prior to procedure) and at 3, 12, 24, 36, 48, and 60 months post their Intracept Procedure. Primary and secondary objectives are based on patient reported outcomes for functional improvement, pain reduction, and physical and mental health pre and post procedure. The study will also look at utilization of injections and pain interventions/surgery for treatment of low back pain post Intracept.

Interventions

radio frequency ablation of the basivertebral nerve for the relief of chronic vertebrogenic low back pain

Sponsors

M Squared Associates, Inc.
CollaboratorINDUSTRY
Relievant Medsystems, Inc.
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

All patients scheduled for the Intracept procedure and whose treating physician is referring to the registry

Exclusion criteria

* No

Design outcomes

Primary

MeasureTime frameDescription
Oswestry Disability Index (ODI) Reduction3 months post procedureValidated questionnaire of low back pain related disability. Comprised of 10 questions evaluating the impact of low back pain on activities of daily living. The ODI is scored on a scale of 0 (no disability) to 100 (complete disability), with categories of 0-20 (minimal disability), 21-40 (moderate disability), 41-60 (severe disability), 61-80 (crippling back pain), and 81-100 (bed-bound or exaggerating). Comparison of mean ODI baseline to 3 months.

Secondary

MeasureTime frameDescription
Numeric Pain Score3, 12, 24, 36, 48 and 60 months post procedureMean reduction in patient reported low back pain from baseline (scale 0 no pain to 10 worst pain imaginable)
Combined Responder Rates (improvement thresholds of ODI ≥ 15 and NPS ≥ 2)3, 12, 24, 36, 48 and 60 months post procedurePercent of responders meeting both thresholds
Oswestry Disability Index (ODI) improvement3, 12, 24, 36, 48 and 60 months post procedureMean improvement in ODI scores from baseline (scale 0 to 100)
Injections utilization compared to baseline3, 12, 24, 36, 48 and 60 months post procedureNumbers of injections post procedure compared to baseline
Post ablation pain interventions/surgeries3, 12, 24, 36, 48 and 60 months post procedureNumbers of pain interventions/surgeries post procedure compared to baseline
PROMIS 29 Change3, 12, 24, 36, 48 and 60 months post procedureMean change in PROMIS-29 from baseline

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026